Stockreport

Does Positive KT-621 Atopic Dermatitis Data Change The Bull Case For Kymera Therapeutics (KYMR)? [Yahoo! Finance]

Kymera Therapeutics, Inc.  (KYMR) 
PDF meaningful improvements in adults with moderate-to-severe atopic dermatitis over 28 days, with a favorable safety profile. The depth of STAT6 degradation in both skin [Read more]